HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

N(6)-carboxymethyllysine (carboxymethyllysine)

Subscribe to New Research on N(6)-carboxymethyllysine

Share|Follow on Twitter

RN given refers to (L)-isomer; structure given in first source

Also Known As:

carboxymethyllysine; N(epsilon)-(carboxymethyl)lysine; N(epsilon)-carboxymethyllysine; NECML

Networked: 100 relevant articles (0 outcomes, 20 trials/studies) for this Bio-Agent, Comments

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins
- Amino Acids: 8726

Experts

1.	Franke, Sybille: 7 articles (01/2008 - 05/2002)
2.	Stein, G: 7 articles (11/2005 - 06/2002)
3.	Franke, S: 7 articles (11/2005 - 06/2002)
4.	Stein, Günter: 6 articles (01/2008 - 05/2002)
5.	Kientsch-Engel, R: 6 articles (11/2004 - 10/2001)
6.	Nagai, Ryoji: 4 articles (02/2010 - 04/2004)
7.	Heidland, August: 4 articles (01/2009 - 01/2002)
8.	Kanazawa, Hiroshi: 3 articles (05/2010 - 07/2008)
9.	Hirata, Kazuto: 3 articles (05/2010 - 07/2008)
10.	Asai, Kazuhisa: 3 articles (05/2010 - 07/2008)

Related Diseases

1.	Inflammation 01/01/2010 - "The present study was designed to determine the validity of measuring CML [N(epsilon)-(carboxymethyl)lysine] levels in ELF for the assessment of small airway inflammation in COPD. " 06/01/2007 - "Since the accumulation of N(epsilon)-(carboxymethyl)lysine (CML), a major antigenic advanced glycation end product, is implicated in tissue disorders in hyperglycemia and inflammation, the identification of the pathway of CML formation will provide important information regarding the development of potential therapeutic strategies for these complications. " 03/01/2004 - "The aim of the study was to investigate the levels of well-characterized AGEs, N(epsilon)-(carboxymethyl)lysine (CML) and N(epsilon)-(carboxyethyl)lysine (CEL) in relation to kidney function and to study the relationship of these AGEs to endothelial function and inflammation in type 1 diabetic patients. " 04/15/2010 - "Taken together, our results demonstrate that puerarin-induced expression of HO-1 is mediated by the PKC delta-Nrf-2-HO-1 pathway and inhibits N-carboxymethyllysine (CML)-induced inflammation in mouse mesangial cells." 04/01/2007 - "METHODS: We examined 172 young (<45 years old) and older (>60 years old) healthy individuals to determine whether the concentration of specific serum AGEs (N(epsilon)-carboxymethyl-lysine [CML] or methylglyoxal [MG] derivatives) were higher in older compared to younger persons and whether, independent of age, they correlated with the intake of dietary AGEs, as well as with circulating markers of OS and inflammation. " Order ALL the reference details at left...
2.	Alzheimer Disease (Alzheimer's Disease) 05/15/2004 - "N epsilon-carboxymethyllysine in brain aging, diabetes mellitus, and Alzheimer's disease." 06/01/1998 - "In this study, we investigated the spatial relationship of the extraneuroperikaryal AGE (carboxymethyllysine and pentosidine) deposits in astrocytes and microglial cells in the Alzheimer's disease brain using double immunolabelling for AGEs and astrocyte or microglial cell markers. " 03/01/2000 - "BACKGROUND: N(epsilon)-carboxymethyllysine (CML) is a product of the oxidative modification of glycated proteins, which damages proteins with ageing, diabetes, uraemia and Alzheimer's disease. " 12/27/1996 - "Advanced glycation end products (AGEs) in the brain were immunohistochemically examined in Alzheimer's disease (AD) and aging using anti-AGE antibody recognizing mainly carboxymethyllysine. " 03/01/2003 - "Pentosidine and N(epsilon)-(carboxymethyl)-lysine in Alzheimer's disease and vascular dementia." Order ALL the reference details at left...
3.	Hypertension (High Blood Pressure) 04/01/2008 - "Whether N(epsilon)-(carboxymethyl)lysine (CML) contributes to the development of hypertension in young spontaneously hypertensive rats (SHR) remains to be established compared to WKY. " 04/01/2008 - "N epsilon-(carboxymethyl)lysine during the early development of hypertension." 10/01/2006 - "The advanced glycation end product N(epsilon)-carboxymethyllysine is not a predictor of cardiovascular events and renal outcomes in patients with type 2 diabetic kidney disease and hypertension." 01/01/2008 - "Serum levels of the advanced glycation end products Nepsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension." 12/01/2006 - "In this study, 12 subjects who were affected by diabetes mellitus and hypertension were subjected to oral antihypertensive therapy with valsartan (class of sartans) with timed sampling of plasma and urine pentosidine, N(epsilon)-(carboxymethyl)lysine (CML), malondialdehyde, and isoprostanes levels, respectively, at baseline and after both 3 and 6 months, with parallel ongoing evaluation of glycemic control and blood pressure levels. " Order ALL the reference details at left...
4.	Amyloidosis 10/01/1998 - "N epsilon-(carboxymethyl)lysine in blood from maintenance hemodialysis patients may contribute to dialysis-related amyloidosis." 10/01/1998 - "BACKGROUND: Recent studies demonstrated not only that advanced glycation end product could be found in amyloid tissue from patient with dialysis related amyloidosis, but also that amyloid beta2-microglobulin was modified with N(epsilon)-(carboxymethyl)lysine (CML). " 03/01/2004 - "We examined immunohistochemically the distribution of 4-hydroxy-2-nonenal (HNE) and N(epsilon)-(carboxymethyl)lysine (CML), markers of lipid peroxidation and advance glycation end products (AGE), respectively, in spleen sections and peritoneal macrophages (MPhi) from mice before and during AA amyloidosis. " 11/01/2001 - "In a previous report, we were the first to describe the increase of circulating carboxymethyllysine-hemoglobin (CML-Hb) levels in hemodialysis patients, particularly in patients with dialysis-related amyloidosis (DRA). " 10/01/1996 - "In conclusion, amyloid beta 2-microglobulin is modified with N epsilon-(carboxymethyl)lysine in dialysis-related amyloidosis." Order ALL the reference details at left...
5.	Abdominal Aortic Aneurysm 08/01/2010 - "Regarding "Serum carboxymethyllysine concentrations are reduced in diabetic men with abdominal aortic aneurysms: Health In Men Study"." 09/01/2009 - "Serum carboxymethyllysine concentrations are reduced in diabetic men with abdominal aortic aneurysms: Health In Men Study." Order ALL the reference details at left...

Related Drugs and Biologics

1.	pentosidine
2.	Malondialdehyde (Propanedial)
3.	Amyloid (Amyloid Fibrils)
4.	imidazolone
5.	Pyruvaldehyde (Methylglyoxal)
6.	N(6)-(1-carboxyethyl)lysine
7.	Biological Markers (Surrogate Marker)
8.	Hemoglobins (Hemoglobin)
9.	Collagen
10.	beta 2-Microglobulin (beta 2 Microglobulin)

Related Therapies and Procedures

1.	Renal Dialysis (Hemodialysis)
2.	Transplantation (Transplant Recipients)
3.	Kidney Transplantation
4.	Renal Replacement Therapy (Therapies, Renal Replacement)
5.	Lenses

blog comments powered by Disqus

TREATMENT OPTIONS
for Inflammation,
Ranking and Evidence

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. Analytic charts allow you and your physicians to see at a glance the treatment options—including new, promising, off-label and experimental.

Free Updates for 1 Year
All 3015 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Evidence References
Sample PDF Report on Psoriasis >>

Price:

$8.50 USD & Delivery via PDF download
updates for 1 year

Research Interface PRO

Rapidly retrieve clinical outcome summaries for all evidence of drug efficacy against any disease in seconds. Click "Charts" to view graphs of relative efficacy of all drugs against any known disease. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time. Save hours of search and analysis time:

Two-clicks from Disease to Drug to Evidence: Drill down to full abstract
Enable Experts: Quickly identify key researchers and their publications
Enable FDA Link Generic: Two-clicks to FDA Products/Patents/Generics
Enable Export: All outcome statements and scores exportable to Excel/TSV for automated meta-analysis
Research Network: Explore drug and disease relationships visually
Enable Mobile Interface: Access from your cellphone, iPhone or PDA

Price:

$45.00 USD access via web interface
1 year subscription

Request Bulk Institution License Details >>